These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35783675)

  • 1. Comparison of the post-marketing safety profile between influenza and COVID-19 vaccines: An analysis of the vaccine adverse event reporting system.
    Al-Ahmari AK; AlAsmari A; AlKorbi A; Ahmed NJ; Almalki ZS; Alshehri AM; Albassam AA; Alem GM
    Saudi Pharm J; 2022 Aug; 30(8):1137-1142. PubMed ID: 35783675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
    Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and Comparison of Adverse Events of Coronavirus Disease 2019 Vaccines Reported to the United States Vaccine Adverse Event Reporting System Between 14 December 2020 and 8 October 2021.
    Zou C; Xue X; Qian J
    Front Med (Lausanne); 2022; 9():826327. PubMed ID: 35449806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Moro PL; Olson CK; Clark E; Marquez P; Strid P; Ellington S; Zhang B; Mba-Jonas A; Alimchandani M; Cragan J; Moore C
    Vaccine; 2022 May; 40(24):3389-3394. PubMed ID: 35489985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
    Moro PL; Ennulat C; Brown H; Woody G; Zhang B; Marquez P; Woo EJ; Su JR
    Drug Saf; 2024 May; 47(5):487-493. PubMed ID: 38411838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Moro PL; Carlock G; Fifadara N; Habenicht T; Zhang B; Strid P; Marquez P
    Vaccine; 2024 Apr; 42(9):2380-2384. PubMed ID: 38462432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
    Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
    Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports.
    Guo W; Deguise J; Tian Y; Huang PC; Goru R; Yang Q; Peng S; Zhang L; Zhao L; Xie J; He Y
    Front Pharmacol; 2022; 13():870599. PubMed ID: 35814246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Woo EJ; Gee J; Marquez P; Baggs J; Abara WE; McNeil MM; Dimova RB; Su JR
    Vaccine; 2023 Jul; 41(30):4422-4430. PubMed ID: 37321898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.
    Myers TR; McNeil MM; Ng CS; Li R; Lewis PW; Cano MV
    Vaccine; 2017 Mar; 35(14):1758-1763. PubMed ID: 28262331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports.
    Riad A; Põld A; Kateeb E; Attia S
    Front Public Health; 2022; 10():952781. PubMed ID: 35899169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD).
    Niu MT; Rhodes P; Salive M; Lively T; Davis DM; Black S; Shinefield H; Chen RT; Ellenberg SS
    J Clin Epidemiol; 1998 Jun; 51(6):503-10. PubMed ID: 9635999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines.
    Albalawi OM; Alomran MI; Alsagri GM; Althunian TA; Alshammari TM
    Saudi Pharm J; 2022 Feb; 30(2):180-184. PubMed ID: 35002372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex and gender differences in adverse events following influenza and COVID-19 vaccination.
    Yin A; Wang N; Shea PJ; Rosser EN; Kuo H; Shapiro JR; Fenstermacher KZJ; Pekosz A; Rothman RE; Klein SL; Morgan R
    Biol Sex Differ; 2024 Jun; 15(1):50. PubMed ID: 38890702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reporting rates for VAERS death reports following COVID-19 vaccination, December 14, 2020-November 17, 2021.
    Day B; Menschik D; Thompson D; Jankosky C; Su J; Moro P; Zinderman C; Welsh K; Dimova RB; Nair N
    Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):763-772. PubMed ID: 36813704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.